Published in Infect Immun on September 11, 2006
Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J Virol (2009) 1.92
Clostridium difficile binary toxin CDT: mechanism, epidemiology, and potential clinical importance. Gut Microbes (2013) 1.41
A role for TLR4 in Clostridium difficile infection and the recognition of surface layer proteins. PLoS Pathog (2011) 1.39
Mouse relapse model of Clostridium difficile infection. Infect Immun (2011) 1.36
Molecular characterization of a Clostridium difficile bacteriophage and its cloned biologically active endolysin. J Bacteriol (2008) 1.28
Cwp84, a surface-associated cysteine protease, plays a role in the maturation of the surface layer of Clostridium difficile. J Biol Chem (2009) 1.25
Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J Infect Dis (2012) 1.25
Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B. Infect Immun (2011) 1.24
Toward a structural understanding of Clostridium difficile toxins A and B. Front Cell Infect Microbiol (2012) 1.22
Clostridium difficile toxins: mediators of inflammation. J Innate Immun (2012) 1.21
Antibody-enhanced, Fc gamma receptor-mediated endocytosis of Clostridium difficile toxin A. Infect Immun (2009) 1.21
Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J Biol Chem (2011) 1.19
Models for the study of Clostridium difficile infection. Gut Microbes (2012) 1.16
Succession in the gut microbiome following antibiotic and antibody therapies for Clostridium difficile. PLoS One (2012) 1.16
Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig Dis Sci (2010) 1.13
Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies. J Infect Dis (2012) 1.09
Bench-to-bedside review: Clostridium difficile colitis. Crit Care (2008) 1.08
A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. Vaccine (2009) 1.08
Clostridium difficile 027/BI/NAP1 encodes a hypertoxic and antigenically variable form of TcdB. PLoS Pathog (2013) 1.08
The enterotoxicity of Clostridium difficile toxins. Toxins (Basel) (2010) 1.07
Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography. J Biol Chem (2014) 1.04
Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A. Vaccine (2008) 1.03
A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model. Clin Vaccine Immunol (2013) 1.03
A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. J Infect Dis (2014) 1.02
Neutralization of Clostridium difficile toxin A using antibody combinations. MAbs (2011) 1.01
Structural determinants of Clostridium difficile toxin A glucosyltransferase activity. J Biol Chem (2012) 0.99
Variations in virulence and molecular biology among emerging strains of Clostridium difficile. Microbiol Mol Biol Rev (2013) 0.99
The potential use of toxin antibodies as a strategy for controlling acute Staphylococcus aureus infections. Expert Opin Ther Targets (2012) 0.98
New advances in the treatment of Clostridium difficile infection (CDI). Ther Clin Risk Manag (2008) 0.98
The host immune response to Clostridium difficile infection. Ther Adv Infect Dis (2013) 0.96
Targeting virulence not viability in the search for future antibacterials. Br J Clin Pharmacol (2015) 0.96
Immune responses to Clostridium difficile infection. Trends Mol Med (2012) 0.95
Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. Infect Immun (2014) 0.94
Passive administration of monoclonal antibodies to anthrolysin O prolong survival in mice lethally infected with Bacillus anthracis. BMC Microbiol (2008) 0.93
Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort study. PLoS One (2014) 0.92
Modulation of toxin production by the flagellar regulon in Clostridium difficile. Infect Immun (2012) 0.92
Engineered single-domain antibodies with high protease resistance and thermal stability. PLoS One (2011) 0.92
Clostridium difficile infection: molecular pathogenesis and novel therapeutics. Expert Rev Anti Infect Ther (2014) 0.92
Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection. Infect Immun (2014) 0.91
Structural basis for antibody recognition in the receptor-binding domains of toxins A and B from Clostridium difficile. J Biol Chem (2013) 0.90
Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes. Antimicrob Agents Chemother (2013) 0.89
Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection. Infect Immun (2011) 0.89
Broad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling. Antimicrob Agents Chemother (2014) 0.88
Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives. Toxins (Basel) (2010) 0.88
Progress towards recombinant anti-infective antibodies. Recent Pat Antiinfect Drug Discov (2009) 0.88
Antibodies for treatment of Clostridium difficile infection. Clin Vaccine Immunol (2014) 0.87
Protective antibody responses against Clostridium difficile elicited by a DNA vaccine expressing the enzymatic domain of toxin B. Hum Vaccin Immunother (2012) 0.84
Immune-based treatment and prevention of Clostridium difficile infection. Hum Vaccin Immunother (2014) 0.84
Protection from Clostridium difficile infection in CD4 T Cell- and polymeric immunoglobulin receptor-deficient mice. Infect Immun (2013) 0.83
An update on antibody-based immunotherapies for Clostridium difficile infection. Clin Exp Gastroenterol (2016) 0.80
An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo. Infect Immun (2014) 0.80
Development and optimization of a novel assay to measure neutralizing antibodies against Clostridium difficile toxins. Clin Vaccine Immunol (2013) 0.80
Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies. Infect Immun (2015) 0.80
Systemically administered IgG anti-toxin antibodies protect the colonic mucosa during infection with Clostridium difficile in the piglet model. PLoS One (2014) 0.79
Disease progression and resolution in rodent models of Clostridium difficile infection and impact of antitoxin antibodies and vancomycin. Antimicrob Agents Chemother (2016) 0.79
Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. Clin Microbiol Rev (2017) 0.78
Identification of human monoclonal antibodies specific for human SOD1 recognizing distinct epitopes and forms of SOD1. PLoS One (2013) 0.78
Structure and function of a Clostridium difficile sortase enzyme. Sci Rep (2015) 0.78
A Combination of Three Fully Human Toxin A- and Toxin B-Specific Monoclonal Antibodies Protects against Challenge with Highly Virulent Epidemic Strains of Clostridium difficile in the Hamster Model. Clin Vaccine Immunol (2015) 0.78
Pseudomembranous colitis due to Clostridium difficile as a cause of perineal necrotising fasciitis. BMJ Case Rep (2013) 0.78
Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin-neutralising immune response. Vaccine (2013) 0.76
Immunogenicity and protective efficacy of Clostridium difficile spore proteins. Anaerobe (2015) 0.75
A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection. Infect Dis Ther (2016) 0.75
Clostridium difficile Infection. Clin Transl Gastroenterol (2015) 0.75
A DNA vaccine targeting TcdA and TcdB induces protective immunity against Clostridium difficile. BMC Infect Dis (2016) 0.75
The roles of toxin A and toxin B in Clostridium difficile infection: insights from the gnotobiotic piglet model. Gut Microbes (2013) 0.75
A Tetraspecific VHH-Based Neutralizing Antibody Modifies Disease Outcome in Three Animal Models of Clostridium difficile Infection. Clin Vaccine Immunol (2016) 0.75
Clostridium difficile-induced colitis in mice is independent of leukotrienes. Anaerobe (2014) 0.75
Recombinant lipoprotein-based vaccine candidates against C. difficile infections. J Biomed Sci (2015) 0.75
Prevalence of diverticulosis in recurrent Clostridium difficile infection. World J Gastroenterol (2010) 0.75
Nonantimicrobial drug targets for Clostridium difficile infections. Future Microbiol (2017) 0.75
Use of a neutralizing antibody helps identify structural features critical for binding of Clostridium difficile toxin TcdA to the host cell surface. J Biol Chem (2017) 0.75
Protection of hamsters from mortality by reducing fecal moxifloxacin concentration with DAV131A in a model of moxifloxacin-induced Clostridium difficile colitis. Antimicrob Agents Chemother (2017) 0.75
Bezlotoxumab: A Review in Preventing Clostridium difficile Infection Recurrence. Drugs (2017) 0.75
An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med (2005) 18.10
Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med (1978) 14.65
Nosocomial acquisition of Clostridium difficile infection. N Engl J Med (1989) 7.72
Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis (1977) 7.68
Clinical practice. Antibiotic-associated diarrhea. N Engl J Med (2002) 7.13
Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med (2000) 6.24
Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature (1995) 6.08
Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev (2005) 5.69
A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol (2005) 5.26
Comparison of two toxins produced by Clostridium difficile. Infect Immun (1981) 5.16
Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg (2002) 4.91
Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet (2001) 4.59
Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol (1997) 3.70
Nosocomial Clostridium difficile colonisation and disease. Lancet (1990) 3.17
Colitis induced by Clostridium difficile. Rev Infect Dis (1980) 3.15
The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins. J Biol Chem (1995) 3.02
Differential effects of Clostridium difficile toxins A and B on rabbit ileum. Gastroenterology (1987) 2.54
Partial purification and characterization of a cytotoxin from Clostridium difficile. Rev Infect Dis (1980) 2.31
Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect Immun (1987) 2.06
Comparative sequence analysis of the Clostridium difficile toxins A and B. Mol Gen Genet (1992) 2.00
Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr (1991) 1.97
A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis (2004) 1.96
Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut (1997) 1.96
Localization of the glucosyltransferase activity of Clostridium difficile toxin B to the N-terminal part of the holotoxin. J Biol Chem (1997) 1.83
Antimicrobial agents implicated in Clostridium difficile toxin-associated diarrhea of colitis. Johns Hopkins Med J (1981) 1.69
Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun (1991) 1.66
Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun (1998) 1.63
Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology (2005) 1.62
Toxin A from Clostridium difficile binds to rabbit erythrocyte glycolipids with terminal Gal alpha 1-3Gal beta 1-4GlcNAc sequences. Arch Biochem Biophys (1987) 1.51
Active and passive immunization to protect against antibiotic associated caecitis in hamsters. Dev Biol Stand (1983) 1.45
Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun (1991) 1.42
Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect Immun (1995) 1.35
Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother (2004) 1.33
Clostridium difficile. Gastroenterol Clin North Am (2001) 1.28
Increased length of hospital stay due to Clostridium difficile associated diarrhoea. Lancet (1995) 1.26
Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun (1999) 1.25
Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrob Agents Chemother (1996) 1.17
Clostridium difficile-associated diarrhoea: epidemiological data from Western Australia. Epidemiol Infect (1994) 0.96
Cytotoxin and enterotoxin production by Clostridium difficile. Microbiologica (1984) 0.94
New method to generate enzymatically deficient Clostridium difficile toxin B as an antigen for immunization. Infect Immun (2000) 0.85
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol (2006) 7.40
Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med (2010) 7.37
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother (2007) 3.32
Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother (2010) 3.06
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res (2007) 2.71
CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A (2004) 2.38
A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res (2007) 2.24
Surface plasmon resonance imaging studies of protein-carbohydrate interactions. J Am Chem Soc (2003) 1.96
Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J Virol (2009) 1.92
Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine (2009) 1.85
Reovirus core protein mu2 determines the filamentous morphology of viral inclusion bodies by interacting with and stabilizing microtubules. J Virol (2002) 1.84
Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. J Virol (2004) 1.79
CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood (2008) 1.74
Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection. J Immunol (2008) 1.69
Proteomic analysis of Schistosoma mansoni egg secretions. Mol Biochem Parasitol (2007) 1.62
Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res (2009) 1.48
CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques. Blood (2006) 1.45
Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis (2005) 1.44
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol (2007) 1.38
Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect Immun (2006) 1.38
Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. PLoS Pathog (2012) 1.35
Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother (2004) 1.34
Template recognition and formation of initiation complexes by the replicase of a segmented double-stranded RNA virus. J Biol Chem (2003) 1.33
The immunobiology of Th1 polarization in high-pathology schistosomiasis. Immunol Rev (2004) 1.27
Reovirus sigma NS protein localizes to inclusions through an association requiring the mu NS amino terminus. J Virol (2003) 1.25
Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters. J Infect Dis (2006) 1.22
T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol Immunother (2012) 1.19
Localization of mammalian orthoreovirus proteins to cytoplasmic factory-like structures via nonoverlapping regions of microNS. J Virol (2009) 1.14
Effective discharge communication in the emergency department. Ann Emerg Med (2012) 1.06
Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood (2002) 1.04
Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A. Vaccine (2008) 1.03
Comparisons of the M1 genome segments and encoded mu2 proteins of different reovirus isolates. Virol J (2004) 1.03
Effect of monophosphoryl lipid A (MPL) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers. Vaccine (2002) 1.00
Virus-derived platforms for visualizing protein associations inside cells. Mol Cell Proteomics (2007) 1.00
The effect of hospital bed occupancy on throughput in the pediatric emergency department. Ann Emerg Med (2009) 0.99
Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins. J Virol Methods (2005) 0.99
Recombinant protein-based assays for detection of antibodies to severe acute respiratory syndrome coronavirus spike and nucleocapsid proteins. Clin Vaccine Immunol (2007) 0.98
A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma. Sarcoma (2013) 0.98
CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells. Biol Blood Marrow Transplant (2010) 0.97
Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: a randomized, dose-escalation phase 1 study in adults. Vaccine (2012) 0.97
Improving timeliness of antibiotic delivery for patients with fever and suspected neutropenia in a pediatric emergency department. Pediatrics (2012) 0.96
Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. Vaccine (2006) 0.95
Enhanced egg-induced immunopathology correlates with high IFN-gamma in murine schistosomiasis: identification of two epistatic genetic intervals. J Immunol (2005) 0.93
Parental language and dosing errors after discharge from the pediatric emergency department. Pediatr Emerg Care (2013) 0.92
History of passive antibody administration for prevention and treatment of infectious diseases. Curr Opin HIV AIDS (2015) 0.92
Loss of activities for mRNA synthesis accompanies loss of lambda2 spikes from reovirus cores: an effect of lambda2 on lambda1 shell structure. Virology (2002) 0.89
Unscheduled return visits to the emergency department: the impact of language. Pediatr Emerg Care (2013) 0.86
Impact of a bronchiolitis guideline on ED resource use and cost: a segmented time-series analysis. Pediatrics (2013) 0.85
Parallel synthesis of glycomimetic libraries: targeting a C-type lectin. Org Lett (2003) 0.85
Insurance status and the care of children in the emergency department. J Pediatr (2012) 0.85
"Left without being seen": a national profile of children who leave the emergency department before evaluation. Ann Emerg Med (2008) 0.84
Affinity maturation of an ERBB2-targeted SPECT imaging peptide by in vivo phage display. Mol Imaging Biol (2014) 0.82
Ultrasound assistance for central venous catheter placement in a pediatric emergency department improves placement success rates. Acad Emerg Med (2014) 0.82
Massachusetts emergency departments' resources and physicians' knowledge of management of traumatic dental injuries. Dent Traumatol (2012) 0.81
Phase I study evaluating the safety and pharmacokinetics of MDX-1303, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin Vaccine Immunol (2011) 0.80
Expansion of CD4 T cells expressing a highly restricted TCR structure specific for a single parasite epitope correlates with high pathology in murine schistosomiasis. Eur J Immunol (2005) 0.79
Identification of human monoclonal antibodies specific for human SOD1 recognizing distinct epitopes and forms of SOD1. PLoS One (2013) 0.78
Pediatric emergency department crowding is associated with a lower likelihood of hospital admission. Acad Emerg Med (2012) 0.78
G glycoprotein amino acid residues required for human monoclonal antibody RAB1 neutralization are conserved in rabies virus street isolates. Antiviral Res (2011) 0.78
Parental Language and Return Visits to the Emergency Department After Discharge. Pediatr Emerg Care (2017) 0.77
Prevalence and predictors of return visits to pediatric emergency departments. J Hosp Med (2014) 0.77
Development of a model of focal pneumococcal pneumonia in young rats. J Immune Based Ther Vaccines (2004) 0.76
Resolving self-association of a therapeutic antibody by formulation optimization and molecular approaches. MAbs (2014) 0.75
Predictors of parent satisfaction in pediatric laceration repair. Acad Emerg Med (2012) 0.75
Improving parent-provider communication in the pediatric emergency department: results from the clear and concise communication campaign. Pediatr Emerg Care (2011) 0.75
Development and evaluation of a program for the use of ultrasound for central venous catheter placement in a pediatric emergency department. Pediatr Emerg Care (2013) 0.75
Risk Factors for Concurrent Suicidal Ideation and Violent Impulses in Military Veterans. Psychol Assess (2017) 0.75
Insurance status and the care of adult patients 19 to 64 years of age visiting the emergency department. Acad Emerg Med (2012) 0.75
Development of a Model to Measure Emergency Department Staffing Limitations. Pediatr Emerg Care (2016) 0.75